← Back to Search

Other

RGT001-075 for Obesity

Phase 2
Waitlist Available
Research Sponsored by Regor Pharmaceuticals Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 weeks
Awards & highlights

Summary

This trial is testing a new medication called RGT001-075 to help overweight individuals lose weight. Participants will be randomly assigned to receive either RGT001-075 or a placebo for 12 weeks

Who is the study for?
This trial is for adults aged 18 to 75 with obesity, defined as having a BMI between 27 and 45. Participants should have maintained a stable body weight for the last three months before starting the trial.
What is being tested?
The study tests RGT001-075 against a placebo to see if it helps with weight loss. Participants will be randomly assigned to receive either RGT001-075 or a dummy pill daily for 12 weeks.
What are the potential side effects?
Potential side effects of RGT001-075 are not specified here, but common weight loss drug side effects may include nausea, constipation, headache, dry mouth, and dizziness.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Secondary study objectives
Change in Body mass index (BMI) in kg/m^2
Change in body weight in kilogram
Change in waist circumference in centimetre
+7 more

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: RGT001-075 GroupExperimental Treatment1 Intervention
Patients will receive once daily dose of study drug for a total of 12 weeks
Group II: Placebo GroupPlacebo Group1 Intervention
Patients will receive once daily dose of matching placebo for a total of 12 weeks

Find a Location

Who is running the clinical trial?

Regor Pharmaceuticals Inc.Lead Sponsor
4 Previous Clinical Trials
86 Total Patients Enrolled
~49 spots leftby Sep 2025